Travere Therapeutics, Inc. Common Stock
TVTXTravere Therapeutics, Inc. (TVTX) is a biotechnology company focused on developing and commercializing therapies for rare andимmunologic diseases. The company's portfolio includes treatments aimed at addressing unmet medical needs in kidney, liver, and rare neurological disorders. Founded with a mission to improve patient outcomes, Travere leverages its expertise in novel drug discovery and development to bring targeted therapies to market.
Company News
Robbins Geller Rudman & Dowd LLP has launched an investigation into Travere Therapeutics, Inc. for potential violations of U.S. federal securities laws. The investigation examines whether Travere and its executives made materially false or misleading statements regarding the company's business and operations. The law firm is seeking investors who...
Travere Therapeutics stock surged nearly 14% on Wednesday following bullish analyst notes. Jefferies analyst Maury Raycroft identified Travere as a potential takeover candidate and highlighted its drug Filspari as having blockbuster potential. Cantor Fitzgerald reported that the FDA appears flexible on approving Filspari for treating focal segmen...
Ligand Pharmaceuticals announced 2026 full year revenue guidance of $245-$285 million, representing a 15% core revenue growth, with strong expectations for royalty revenue from key pharmaceutical products.
The American Kidney Fund hosted its third annual Patient Access Initiative Summit focusing on innovative kidney care technologies, AI applications, and addressing barriers to kidney disease prevention and treatment.
